Poster Sessions
Tuesday, 2 May 2023 - 04:15 - 06:15 p.m.
Room: Conference 3C - ePoster station 1
Chair: Claus Lindbjerg Andersen, Denmark
PS-01-001: Investigating Homologous Recombination Deficiency in mCRPC through ctDNA
Georgios Vlachos, Austria
Abstract
PS-01-002: Identification of Therapeutically Relevant Mutations in Circulating Tumor DNA at Baseline to Assist in Treatment Decision Making
Paul van der Leest, The Netherlands
Abstract
PS-01-003: Epigenetic Biomarker Identification in Prostate Cancer using Liquid Biopsy Approaches
Rakesh Trivedi, United States
Abstract
PS-01-005: Detection of minimal residual disease in acute myeloid leukemia using microfluidics
Alexandra Teixeira, Portugal
Abstract
PS-01-006: Optimization of the characterization of plasma cell-free DNA integrity using a droplet-based digital PCR multiplex assay: towards the development of circulating tumor DNA multiplex assay
Valerie Taly, France
Abstract
PS-01-007: ddPCR, qPCR, and NGS performance to detect KRAS and EGFR mutations in plasma cell-free DNA of stage IIIB/IV lung adenocarcinoma patients, and comparison with the tissue molecular profile
Ernst Jan Speel, The Netherlands
Abstract
PS-01-008: Cross-Platform Biomarker Program for Establishment and Validation of Liquid Biopsy for Clinical Decision Making in resectable Gastrointestinal Stromal Tumour (GIST)
Helen Sievert, Germany
Abstract
PS-01-009: Identifying the Levers of Cost-Effectiveness of Next-Generation-Sequencing-Based Liquid Biopsy for Colorectal Cancer in France, Spain, and Germany
Wendelin Schramm, Germany
Abstract
PS-01-010: Quantitative detection of cell free HPV DNA in plasma samples using Nanopore Sequencing
Oliver Schauer, Germany
Abstract
PS-01-011: Clonal tracking and monitoring of minimal residual disease using longitudinal whole-genome sequencing of solid tumors and liquid biopsies in rectal cancer
Francisco Sanchez-Vega, United States
Abstract
PS-01-012: PLCRC-PROVENC3: assessing the prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients
Carmen Rubio-Alarcón, The Netherlands
Abstract
PS-01-013: Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using The Plasma-SeqSensei™ NSCLC RUO Kit at diagnostic in Lyon’s hospital
Léa Payen, France
Abstract
PS-01-014: KRAS and GNAS mutations in cell-free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms – an observational pilot-study regarding the risk of progression to pancreatic cancer
Christine Nitschke, Germany
Abstract
PS-01-015: Comparative study of streptavidin-coupled ferrofluids and magnetic beads for capture of circulating tumor cells in patients with disseminated prostate cancer
Amalie Mundt Jørgensen, Denmark
Abstract
PS-01-016: Circulating BRAF V600E levels as a biomarker for disease presence and activity in Langerhans Cell Histiocytosis
Elisabeth Mellström, Sweden
Abstract
PS-01-017: Towards a minimally invasive method for diagnosing aggressive SCCs in 'butterfly disease'
Albert Mellick, Australia
Abstract
PS-01-018: Improved detection of disease progression in metastatic breast cancer by absolute molecular counting: the 100 copies/mL question
Geert Martens, Belgium
Abstract
PS-01-019: Analysis of Cell-Free DNA in the Plasma of patients with Non-Resectable, Progressive or Relapsed Pediatric Malignancies
Kendra Maass, Germany
Abstract
PS-01-020: C-ProMeta-1: Predicting treatment failure after radical prostatectomy using circulating tumour cells
Rachel Lawrence, United Kingdom
Abstract
PS-01-021: High tumor metabolic activity is associated with circulating tumor DNA detection in early-stage lung cancer patients
Anine Larsen Ottestad, Norway
Abstract
PS-01-023: Comparison of circulating tumor cell enrichment techniques considering tumor heterogeneity
Minseok S. Kim, Republic of Korea
Abstract
PS-01-024: Blood-based detection of lung cancer using cysteine-rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker
Lucija Ackar, Germany
Abstract
Room: Conference 3D - ePoster station 2
Chair: Claudia Koch, Germany
PS-02-001: Analysis of circulating tumor cells displays tumor heterogeneity in advanced prostate cancer
Lina Merkens, Germany
Abstract
PS-02-002: Characterisation of novel, patient-like cfDNA reference material for molecular diagnostic liquid biopsy assays
Björn Nowack, Germany
Abstract
PS-02-003: Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients
Keren Bahar-Halpern, Israel
Abstract
PS-02-004: Monitoring treatment efficacy using personalised circulating-tumour DNA panels in patients with metastatic breast cancer
Pia Mouhanna, Sweden
Abstract
PS-02-005: TNC positive extracellular vesicles as clinical biomarkers in glioblastoma
Amanda Salviano da Silva, Germany
Abstract
PS-02-006: Liquid biopsy in colorectal cancer beyond targeted analysis of single variants
Ariane Hallermayr, Germany
Abstract
PS-02-007: Transcriptomic analysis of circulating tumor cells in metastatic breast cancer: the new frontiers of liquid biopsy for personalized medicine
Tania Rossi, Italy
Abstract
PS-02-008: Single-center prospective study to evaluate circulating tumor cells as a monitoring tool in women with early breast cancer treated with neoadjuvant chemotherapy
Sohyun Moon, Republic of Korea
Abstract
PS-02-009: Deep learning for Circulating Tumor Cell (CTC) identification with the CELLSEARCH system: towards optimal standardization
Luca Biasiolli, Italy
Abstract
PS-02-010: It's a match - circulating tumor DNA in urine and plasma reveal complementary information in prostate cancer
Tina Moser, Austria
Abstract
PS-02-011: ctDNA testing in treatment response monitoring of patients with metastatic colorectal cancer: the DOLPHIN study
Denise van Steijn, The Netherlands
Abstract
PS-02-013: Advancing Single-Cell Proteomics with ZeptoCTC: A high-sensitivity method for analysis of Circulating Tumor Cells
Mahdi Rivandi, Germany
Abstract
PS-02-014: Comparison of DNA reference material for pre-analytics: Nucleosomal plasma-spike-ins reveal true recovery efficiencies of circulating cell-free DNA extractions
Tu Truong, Germany
Abstract
PS-02-015: Spotting the difference: rare cell characterization by multiplex mRNA in situ hybridization and machine learning in the context of liquid biopsy-based therapy resistance monitoring
Lilli Bonstingl, Austria
Abstract
PS-02-016: Liquid biopsy from Bile - a potential novel biomarker in biliary stenosis
Eva Dazert-Klebsattel, Germany
Abstract
PS-02-017: Comparative analysis of EpCAM High-Expressing and Low-Expressing Circulating Tumor Cells with regard to their clonal relationship and clinical value
André Franken, Germany
Abstract
PS-02-018: The DKTK EXLIQUID consortium – Exploiting liquid biopsies for molecular tumor board patients
Christof Winter, Germany
Abstract
PS-02-019: “Inner Allergy” – increased basal serum tryptase levels due to Hereditary Alpha-Tryptasemia and / or KIT D816V mutation may explain mast cell related symptoms
Eva Dazert-Klebsattel, Germany
Abstract
PS-02-020: Detecting and monitoring circulating tumour DNA in dried blood spots from metastatic cancer patients and xenograft mouse models
Angela An, United Kingdom
Abstract
PS-02-021: SNP detection by hyperplex digital PCR for patient sample identification
Martin Becker, France
Abstract
PS-02-023: A web-based cohort monitoring dashboard for multi-center clinical studies with biospecimens within the German Cancer Consortium (DKTK)
Patrick Skowronek, Germany
Abstract
PS-02-024: Results from an international inter-lab study of CTC enrichment and enumeration on the Genesis Rare Cell Isolation System
Adam Corner, United States
Abstract
Room: Conference 3D - ePoster station 3
Chair: Basant Kumar Thakur, Germany
PS-03-001: Functional analysis of live circulating tumor cells from triple negative breast cancer patients using TetherChip technology
Vasileios Vardas, Greece
Abstract
PS-03-002: Retinoic acid-induced 2 driven polymerization of C-terminal binding proteins as novel mechanism of transcriptional regulation in castration-resistant prostate cancer
Stefan Werner, Germany
Abstract
PS-03-003: Binding of circulating melanoma cell-derived extracellular vesicles to ultra-large von Willebrand factor induces cancer-associated thrombosis
Yuanyuan Wang, Germany
Abstract
PS-03-004: p53-binding protein 1 accumulation in circulating tumor cells identifies chemotherapy-responsive metastatic breast cancer patients
Kathrin Niedermayer, Germany
Abstract
PS-03-005: RAI2 controls polycomb-mediated repression of CDKN1A by its interaction with CtBP1
Sarah Greimeier, Germany
Abstract
PS-03-006: Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
Leonie Ott, Germany
Abstract
PS-03-008: Circulating tumour cell clusters in the metastatic development of prostate cancer
Edwina Burke, United Kingdom
Abstract
PS-03-009: Evaluation of the anti-tumor effects of artesunate on Circulating Tumor Cells (CTCs)
Galatea Kallergi, Greece
Abstract
PS-03-010: Evaluation of cell-free miR2110 in hepatocellular carcinoma patients’ liquid biopsies
Pelin Balcik Ercin, Turkey
Abstract
PS-03-011: In vitro biological effects of breast cancer circulating cell free DNA on normal breast cells
Ekaterini Alexiou Chatzaki, Greece
Abstract
PS-03-012: Targeted treatments in gastric adenocarcinoma circulating tumour cells: Is combination therapy the answer?
Ann-Katrin Piper, Australia
Abstract
PS-03-013: RAI2 as novel suppressor of cancer cell dissemination to the bone marrow
Thais Pereira-Veiga, Germany
Abstract
PS-03-014: Targeting BCAT1 is a metabolic vulnerability that impairs cell proliferation and aggressiveness in renal cell carcinoma
Pouria Jandaghi, Canada
Abstract
PS-03-015: Circulating tumor cells in breast cancer patients with Leptomeningeal Metastases: Detection and in vitro expansion
Laure Cayrefourcq, France
Abstract
PS-03-016: Epigenomic analysis reveals a specific DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer
Angel Diaz-Lagares, Spain
Abstract
PS-03-017: Ultra-sensitive Minimal Residual Disease (MRD) monitoring for cancer patients using SuperRCA mutation assays with Flow Cytometer Readout
Lei Chen, Sweden
Abstract
PS-03-018: The feasible approach to monitor the MRD for recurrence after the radical treatment for stage III colorectal cancer cases
Koshi Mimori, Japan
Abstract
PS-03-019: Evaluation of treatment response in paediatric leukaemia using patient specific circulating tumour DNA analysis
Fani Pujol Calderón, Sweden
Abstract
PS-03-020: Ultrasensitive amplicon based detection of circulating tumour DNA for identification of minimal residual disease
Stefan Filges, Sweden
Abstract
PS-03-021: Development of a target-capture NGS assay for use in molecular-based research of myeloid Measurable Residual Disease
Rebecca Biloune, United Kingdom
Abstract
PS-03-022: Noninvasive, dynamic risk profiling of aggressive B-cell lymphomas by peripheral blood circulating tumor DNA sequencing
Sven Borchmann, Germany
Abstract
PS-03-023: Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients
Karin Birkenkamp-Demtröder, Denmark
Abstract
PS-03-024: ctDNA BRCA1-methylation can predict therapy efficacy in ovarian and breast cancer patients
Simon Joosse, Germany
Abstract
Wednesday, 3 May 2023 - 04:30 - 06:30 p.m.
Room: Conference 3C - ePoster station 1
Chair: Katja Weisel, Germany
PS-04-001: Immune checkpoints and epithelial to mesenchymal transition related molecules in triple negative breast cancer patients’ circulating tumor cells and their clinical impact
Vasileios Vardas, Greece
Abstract
PS-04-002: Expression of CXCR4, JUNB and PD-L1 in circulating tumor cells isolated from patients with prostate cancer
Argyro Roumeliotou, Greece
Abstract
PS-04-003: Detection of circulating tumor cells (CTCs) in patients with metastatic uveal melanoma - a pilot study
Shari Schneider, Germany
Abstract
PS-04-004: Circulating microRNAs as predictors of response to therapy in melanoma
Luigi Fattore, Italy
Abstract
PS-04-005: The winning liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer
Zahra Eslami Samarin, France
Abstract
PS-04-006: Assessment of CTLA4 and TIGIT expression on CTCs and PBMCs of patients with small cell lung cancer (SCLC)
Maria A. Papadaki, Greece
Abstract
PS-04-007: Cost-effectiveness analysis of cell-free DNA-based molecular tumor profiling platforms for the detection of EGFR mutations in lung cancer
Pim Rozendal, The Netherlands
Abstract
PS-04-008: Early detection of prostate cancer by investigating the host peripheral immune response
Junjie Chai, United Kingdom
Abstract
PS-04-009: CTC identification enhanced specificity by using a double exclusion biomarker assay
Adriana Carneiro, Portugal
Abstract
PS-04-011: Porous bioaffinity membranes for the isolation of circulating tumor cells
Thomas Brandstetter, Germany
Abstract
PS-04-012: Mixed MiRNA and Serum-marker Classifier for Prediction of Immunotherapy Response in Liquid Biopsies of Melanoma Patients
Marc Bender, Germany
Abstract
PS-04-013: Circulating miRNA compositions in liquid biopsies of melanoma patients as biomarker candidates for progression, PD-L1 status and overall survival
Sarah Degenhardt, Germany
Abstract
PS-04-014: ctDNA monitoring of metastatic melanoma patients receiving immunotherapy
Isabel Heidrich, Germany
Abstract
PS-04-015: D-Dimers as a liquid prognostic biomarker in melanoma patients treated with immune-checkpoint inhibitors
Tim Zell, Germany
Abstract
PS-04-016: Exosomal NGFR witnesses the dynamics of inflammation-induced dedifferentiation in TNF-α-treated melanoma cells
Benjamin Deitert, Germany
Abstract
PS-04-017: Circulatory plasma proteomic biomarkers predict response to immunotherapy in melanoma patients and reveal biological insights into the tumor microenvironment
Marijana Rucevic, France
Abstract
PS-04-018: Diagnosis of precancerous high-grade cervical lesions and cervical cancer with a panel of circulating cell-free microRNAs in a liquid biopsy approach
Annika Tamenang, Germany
Abstract
PS-04-019: Von Willebrand factor predicts response to immunotherapy in patients with metastatic melanoma
Julian Kött, Germany
Abstract
PS-04-020: Extracellular vesicle trafficking in GBM
Amanda Salviano da Silva, Germany
Abstract
PS-04-021: Th1/Tc1 polarized tissue resident memory T cells mediate checkpoint blockade–induced dermatitis and colitis via IFNγ and TNFα
Robin Reschke, United States
Abstract
PS-04-022: Analyzing tumor microenvironment difference between TNBC subtypes by meta-analysis of 7 breast cancer scRNAseq studies
Kyungsoo Kim, Republic of Korea
Abstract
Room: Conference 3D - ePoster station 2
Chair: Paul Hofman, France
PS-05-001: The role of circulating tumor cells in the course of disease and therapy of high-grade-serous ovarian cancer patients
Annabelle Lobermeyer, Germany
Abstract
PS-05-002: Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma
Benjamin Stubbe, Denmark
Abstract
PS-05-003: Multi-platform analysis of the heterogeneity of circulating melanoma cells and tumor DNA as useful tool to track disease evolution and targeted therapy response
Maria Chiara Scaini, Italy
Abstract
PS-05-004: Targeted mutation detection in individual circulating tumor cells using a modified UltraSEEK® workflow for the MassARRAY® System
Laura Keller, Germany
Abstract
PS-05-005: Ultrasensitive molecular residue disease detection enabled by genome wide concatmer error correction
Paul Tang, United States
Abstract
PS-05-006: Investigating potential circulating tumor cell release following breast cancer biopsy
Nikhil Kalra, Germany
Abstract
PS-05-007: New droplet digital PCR for highly sensitive detection of microsatellite instability
Valerie Taly, France
Abstract
PS-05-008:Liquid biopsy beyond cancer – circulating epigenetic biomarkers in cardiovascular and immune-mediated diseases
Lucia Ciglar, Austria
Abstract
PS-05-009: A novel, automated approach providing standardized sample preparation for multiple Liquid Biopsy analyses
Roberta Carbone, Italy
Abstract
PS-05-010: Evaluation of new therapeutic targets in circulating tumor cells and exosomes isolated from small cell lung cancer patients
Dimitrios Papakonstantinou, Greece
Abstract
PS-05-011: Association of CTC and MTV in pancreatic cancer
Hyun Soo Shin, Republic of Korea
Abstract
PS-05-012: Possible role of circulating tumour cells (CTCs) for outcome prediction of salvage lymph node dissection in patients with early prostate cancer recurrence
Tobias Maurer, Germany
Abstract
PS-05-013: Microfluidic detection of circulating tumor cells from pediatric sarcoma patients
Minh-Chau Le, United States
Abstract
PS-05-014: Personalised analysis of circulating tumor DNA as a novel biomarker in neuroblastoma
Ida Rahmqvist, Sweden
Abstract
PS-05-015: Marker-independent enrichment of circulating tumor cells from leukapheresis by non-tumor cell depletion
Lena Willnow, Germany
Abstract
PS-05-016: Detection of circulating tumor cells from a multi-cancer cohort using the recombinant malaria protein rVAR2
Caroline Løppke, Denmark
Abstract
PS-05-018: The role of circulating tumor cells in vulvar carcinoma
Leonie Elisabeth Kleinholz, Germany
Abstract
Room: Conference 3D - ePoster station 3
Chair: Ellen Heitzer, Austria
PS-06-001: Circadian rhythm and circulating cell-free DNA release on healthy subjects
Valerie Taly, France
Abstract
PS-06-002: Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
Florian Janke, Germany
Abstract
PS-06-003: Monitoring response to targeted treatment in children with ALK-driven neuroblastoma using a novel assay for detection of circulating tumor DNA
Raghda Ibrahim, Sweden
Abstract
PS-06-004: Self-supervised learning for detection and classification of circulating tumor cells in liquid biopsy data
Hümeyra Husseini, Germany
Abstract
PS-06-005: Use of a highly sensitive and specific minimal residual disease test to characterize novel cell-free DNA reference material
Annett Helfrich-Kröger, Germany
Abstract
PS-06-006: Detection of multiple HPV types in liquid biopsies of cervical neoplasia
Johanna Herbst, Germany and Vanessa Vohl, Germany
Abstract
PS-06-007: Impact of reference materials for analytical performance evaluation of liquid biopsy NGS assays
Ariane Hallermayr, Germany
Abstract
PS-06-008:Feasibility and efficacy of adjuvant chemotherapy in stage II colon cancer patients with detectable circulating tumor DNA after surgery
Ingrid Franken, The Netherlands
Abstract
PS-06-009: ExTarget– Circulating tumor DNA profiling for response assessment and MRD monitoring in molecular tumor board patients
Stephanie Fliedner, Germany
Abstract
PS-06-010: Monitoring the release of tumor cells before, during and after prostatectomy
Gresa Emurlai, Germany
Abstract
PS-06-011: Performance of ddPCR and qPCR to detect cell-free HPV16 DNA in liquid biopsies from patients with HPV-related oropharyngeal squamous cell carcinoma at diagnosis and recurrence
Imke Demers, The Netherlands
Abstract
PS-06-012: Cell-free tumor DNA analysis during immunotherapy to monitor clinical response for patients with non-small cell lung cancer
Anna Rohlin, Sweden
Abstract
PS-06-013: UCCSH NGSP: Improvement of molecular tumor board decisions with a ctDNA-based deep scale cross-entity NGS panel
Eva Dazert-Klebsattel, Germany
Abstract
PS-06-014: Evaluation of a multi-omics approach to molecular residual disease detection
Archana Ramesh, United States
Abstract
PS-06-015: Exploring the clinical relevance of circulating tumor cells and tumor-derived extracellular vesicles collected from different blood compartments in colorectal cancer patients
Stefan Cieslik, Germany
Abstract
PS-06-016: A targeted-enzymatic-methyl-seq approach for cell-free DNA methylation analysis to improve cancer detection, disease following and minimal residual disease monitoring
Mehdi Ben Sassi, France
Abstract
PS-06-017: Identification of atypical cells in the blood of non-small cell lung cancer (NSCLC) patients
Yassine Belloum, Germany
Abstract
PS-06-018: Integrated circulating tumor DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
Arlou Kristina Angeles, Germany
Abstract
PS-06-019: Gene methylation and levels of circulating tumor DNA as diagnostic/prognostic biomarkers in Pancreatic Cancer: biosignatures built via automated Machine Learning
Ekaterini Alexiou Chatzaki, Greece
Abstract
PS-06-020: Classification of brain tumors by Nanopore sequencing of cell-free DNA from cerebrospinal fluid
Ann-Kristin Afflerbach, Germany
Abstract
PS-06-021: OUTLIVE-CRC: Improvement of prognosis of young colorectal cancer patients through multimarker models and nutritional medical intervention – focus on liquid biopsy-based ctDNA genomics
Eva Dazert-Klebsattel, Germany
Abstract
PS-06-022: Extracellular vesicle (EV) associated DNA: potential liquid biopsy biomarker and functional communicators in cancer
Basant Kumar Thakur, Germany
Abstract
General note on the poster sessions
In the above listed poster sessions we have only disclosed the presenting authors. The full details including co-authors can be found in the linked abstracts.